December 3, 2018 / 7:18 AM / 13 days ago

BRIEF-Oxford BioMedica Notes Longer-Term Analyses From Pivotal Kymriah Trials

Dec 3 (Reuters) - Oxford Biomedica Plc:

* NOTES AN ANNOUNCEMENT BY NOVARTIS ON LONGER-TERM ANALYSES OF BOTH ELIANA AND JULIET PIVOTAL TRIALS

* OXFORD BIOMEDICA-KYMRIAH CONTINUED TO DEMONSTRATE STRONG EFFICACY WITH DURABLE RESPONSES AND MAINTAINED CONSISTENT AND WELL-CHARACTERISED SAFETY PROFILE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below